Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma ...
Ciltacabtagene autoleucel (cilta-cel) showed significant progression-free survival (PFS) benefits in multiple myeloma patients with poor prognostic features, including high-risk cytogenetics and triple-class refractoriness, in the CARTITUDE-4 trial. 12-month PFS rates exceeded 82% across various high-risk subgroups, affirming cilta-cel's effectiveness in a broad patient population.
Reference News
Ciltacabtagene autoleucel (cilta-cel) showed significant progression-free survival (PFS) benefits in multiple myeloma patients with poor prognostic features, including high-risk cytogenetics and triple-class refractoriness, in the CARTITUDE-4 trial. 12-month PFS rates exceeded 82% across various high-risk subgroups, affirming cilta-cel's effectiveness in a broad patient population.